Research
Hormonal
Leptin resistance in obesity is mechanistically linked to the overexpression of negative regulators of leptin signaling, specifically SOCS-3 and PTP1B, in the hypothalamus.
Leptin resistance isn't just about 'willpower'; it involves specific proteins (SOCS-3, PTP1B) that block the signal in your brain. Research is targeting these specific proteins to develop drugs that could restore sensitivity.
GoodSupportsHIGH confidence
Novel players in negative regulation of central leptin receptor signaling have been identified and open the possibility that these may be important in the development of leptin resistance and obesity.
Why this rating
Strong evidence from knockout mice (PTP1B-/-) showing hypersensitivity to leptin, though human data is less definitive.
Source
Leptin Signaling in the Central Nervous System and the Periphery
Christian Bjørbæk · Recent Progress in Hormone Research · 2004
DOI 10.1210/rp.59.1.305
narrative_reviewCited 554×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Central nervous system leptin signaling regulates energy balance and body weight primarily through the JAK-STAT3 pathway acting on hypothalamic neurons, specifically by activating pro-opiomelanocortin (POMC) neurons and inhibiting neuropeptide Y (NPY)/agouti-related protein (AgRP) neurons.Strong
- Leptin has direct peripheral actions on immune cells, pancreatic beta cells, adipocytes, and skeletal muscle, influencing processes like fatty acid metabolism and insulin sensitivity.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →